Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

By V. Brinkmann, A. Billich, T. Baumruker, P. Heining, R. Schmouder, G. Francis, S. Aradhye, P. Burtin. Nature reviews. Drug discovery, 2010

1,137 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Microglia Polarization From M1 to M2 in Neurodegenerative Diseases (2022, background): “Carta and Pisanu (2013) elaborated that PPAR-γ located in the SNc. PPAR-γ agonists exert a neuroprotective effect on PD by preventing the loss of DA neurons in the SNc (Carta, 2013).”
Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection (2011, positive): “Due to the immunomodulatory properties of S1P receptor signaling, chemical agonists have been used successfully for the treatment of relapsing and remitting multiple sclerosis (Brinkmann et al., 2010).”
Sequential regulatory activity prediction across chromosomes with convolutional neural networks (2017, background): “Despite the fact that the multiple sclerosis GWAS literature does not highlight GPR65 , sphingolipid metabolism has emerged as a therapeutic target for MS via the drug fingolimod, a sphingosine analogue that alters immune cell trafficking and is now in clinical use (Brinkmann et al. 2010) .”